BioAtla, Inc. (NASDAQ:BCAB) Q4 2022 Earnings Call Transcript

Philippe Martin: Yes, so it is atypical. There hasn’t been that many but so far it is a typical design for a bispecific CD3 T cell engager. The FDA is particularly concerned about cytokine release storm that have been observed with some other CD3 bispecific and so this is all set up to try to mitigate all this and make sure that we’re not putting patients at risk. We have not seen any during our talk study neither have we seen neurotoxicity or even infusion reactions but we still have to follow that type of design in case we were to see grade two and above cytokine release syndrome. So that’s really all done to manage that. The accelerated titration phase is fast. It is one patient per cohort is it a 14 days DLT observation period.

So we can go through it relatively quickly and then move into a more standard titration at those levels that we believe will be efficacious. These drugs are extremely potent and so that is why we’re starting at that low of a dose to begin with. But that is not, all of this is not atypical, is what I’m trying to tell you.

Operator: And we have reached the end of the question and answer session. I’ll now turn the call back over to Jay Short for closing remarks.

Jay Short: Well, I want to thank everyone for their time today and also thank the BioAtla team. And we look forward to speaking with you again, at least in May with our next quarterly earnings call. Thank you.

Operator: And this concludes today’s conference. And you may disconnect your lines at this time. Thank you for your participation.